CY1896A - Pharmaceutical preparation with extended release of a dihydropyridine and a beta-adrenoreceptor antagonist and a process for the preparation thereof - Google Patents

Pharmaceutical preparation with extended release of a dihydropyridine and a beta-adrenoreceptor antagonist and a process for the preparation thereof

Info

Publication number
CY1896A
CY1896A CY189696A CY189696A CY1896A CY 1896 A CY1896 A CY 1896A CY 189696 A CY189696 A CY 189696A CY 189696 A CY189696 A CY 189696A CY 1896 A CY1896 A CY 1896A
Authority
CY
Cyprus
Prior art keywords
preparation
dihydropyridine
beta
extended release
adrenoreceptor antagonist
Prior art date
Application number
CY189696A
Other languages
English (en)
Original Assignee
Haessle Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20369795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1896(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Haessle Ab filed Critical Haessle Ab
Publication of CY1896A publication Critical patent/CY1896A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY189696A 1987-10-08 1996-09-27 Pharmaceutical preparation with extended release of a dihydropyridine and a beta-adrenoreceptor antagonist and a process for the preparation thereof CY1896A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8703881A SE8703881D0 (sv) 1987-10-08 1987-10-08 New pharmaceutical preparation

Publications (1)

Publication Number Publication Date
CY1896A true CY1896A (en) 1996-09-27

Family

ID=20369795

Family Applications (1)

Application Number Title Priority Date Filing Date
CY189696A CY1896A (en) 1987-10-08 1996-09-27 Pharmaceutical preparation with extended release of a dihydropyridine and a beta-adrenoreceptor antagonist and a process for the preparation thereof

Country Status (26)

Country Link
US (1) US4942040A (xx)
EP (1) EP0311582B1 (xx)
JP (1) JP2619936B2 (xx)
KR (1) KR960009411B1 (xx)
CN (1) CN1029935C (xx)
AT (1) ATE84412T1 (xx)
AU (1) AU615211B2 (xx)
CA (1) CA1312286C (xx)
CY (1) CY1896A (xx)
DE (1) DE3877492T2 (xx)
DK (1) DK175085B1 (xx)
ES (1) ES2053815T3 (xx)
FI (1) FI92903C (xx)
GR (1) GR3006788T3 (xx)
HK (1) HK6296A (xx)
HU (1) HU210461A9 (xx)
IE (1) IE63084B1 (xx)
IL (1) IL87922A (xx)
IS (1) IS1584B (xx)
MX (1) MX169243B (xx)
MY (1) MY104065A (xx)
NO (1) NO177375C (xx)
NZ (1) NZ226245A (xx)
PH (1) PH25568A (xx)
PT (1) PT88711B (xx)
SE (1) SE8703881D0 (xx)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268182A (en) * 1988-06-24 1993-12-07 Abbott Laboratories Sustained-release drug dosage units of terazosin
GB9025251D0 (en) * 1990-11-20 1991-01-02 Solomon Montague C Nifedipine dosage forms
EP0677291A3 (en) * 1991-03-18 1996-08-07 Sepracor Inc Composition and method containing optically pure S-metoprolol.
US5834496A (en) * 1991-12-02 1998-11-10 Sepracor, Inc. Methods for treating hypertension using optically pure S(-) felodipine
IL104192A (en) * 1992-02-17 1998-01-04 Siegfried Ag Pharma Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US5399358A (en) * 1993-11-12 1995-03-21 Edward Mendell Co., Inc. Sustained release formulations for 24 hour release of metroprolol
US5399359A (en) * 1994-03-04 1995-03-21 Edward Mendell Co., Inc. Controlled release oxybutynin formulations
JP3279318B2 (ja) * 1994-04-25 2002-04-30 ペンウェスト ファーマシューティカルズ カンパニー 持続放出性賦形剤
US5399362A (en) * 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
AU2068797A (en) * 1996-01-29 1997-08-20 Edward Mendell Co. Inc. Sustained release excipient
US5783212A (en) * 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
IL123505A (en) 1996-07-08 2004-12-15 Penwest Pharmaceuticals Compan Sustained release matrix for high-dose insoluble drugs
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
CA2354057C (en) * 1998-12-11 2009-02-10 Nostrum Pharmaceuticals, Inc. Sustained release tablet containing hydrocolloid and cellulose ether
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
EP1135106B1 (en) * 1999-09-30 2008-04-09 Penwest Pharmaceuticals Co. Sustained release matrix systems for highly soluble drugs
CN1407884B (zh) 1999-10-29 2012-06-20 欧罗赛铁克股份有限公司 控释氢可酮制剂
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
TWI246921B (en) * 2000-04-11 2006-01-11 Sankyo Co Stabilized pharmaceutical composition with calcium blocker
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
MXPA03003895A (es) 2000-10-30 2003-07-28 Euro Celtique Sa Formulaciones de hidrocodona de liberacion controlada.
JP4440635B2 (ja) * 2001-07-06 2010-03-24 エンドー ファーマシューティカルズ， インコーポレイティド オキシモルホン放出制御性処方物
ES2296898T3 (es) * 2001-09-14 2008-05-01 Scolr, Inc. Forma de dosificacion oral de liberacion prolongada modulada por aminoacidos.
US20040009220A1 (en) * 2001-12-31 2004-01-15 Vinay Sharma Rate-controlled beta blockers and process for forming same
CA2481091A1 (en) * 2002-04-05 2003-10-23 Penwest Pharmaceuticals Co. Sustained release metoprolol formulations
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
US7276514B2 (en) * 2002-05-15 2007-10-02 Charitable Leadership Foundation - Medical Technology Acceleration Program Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof
US20050267143A1 (en) * 2002-05-15 2005-12-01 Davis Paul J Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof
US20080051428A1 (en) * 2002-05-15 2008-02-28 Davis Paul J Pyrroloquinoline quinone drugs and methods of use thereof
KR20030095600A (ko) * 2002-06-12 2003-12-24 환인제약 주식회사 펠로디핀을 포함하는 제어방출형 조성물 및 그 제조방법
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
US20070092573A1 (en) 2005-10-24 2007-04-26 Laxminarayan Joshi Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist
TW200806648A (en) * 2005-11-29 2008-02-01 Sankyo Co Acid addition salts of dihydropyridine derivatives
TW200736245A (en) * 2005-11-29 2007-10-01 Sankyo Co Acid addition salts of optically active dihydropyridine derivatives
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
EP2255791B1 (en) * 2009-04-03 2011-11-16 Zaklady Farmaceutyczne Polpharma SA Extended release pharmaceutical composition comprising metoprolol succinate
US8927025B2 (en) 2010-05-11 2015-01-06 Cima Labs Inc. Alcohol-resistant metoprolol-containing extended-release oral dosage forms
MX2012013021A (es) * 2010-05-11 2012-12-17 Cima Labs Inc Formulaciones resistentes a alcohol.
AU2012303683B2 (en) * 2011-08-26 2016-09-08 Wockhardt Limited Methods for treating cardiovascular disorders
GB2512059B (en) * 2013-03-18 2016-08-31 Rolls Royce Plc An independently moveable machine tool
CN113143877A (zh) * 2021-05-07 2021-07-23 苏州康恒研新药物技术有限公司 一种琥珀酸美托洛尔微丸缓释片的制备方法
CN114712319B (zh) * 2022-03-25 2024-01-09 北京诺康达医药科技股份有限公司 一种非洛地平盐酸普萘洛尔复方制剂及其制备方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
CH532038A (de) * 1970-05-25 1972-12-31 Ciba Geigy Ag Verfahren zur Herstellung von neuen Cycloheptenderivaten
US3951821A (en) * 1972-07-14 1976-04-20 The Dow Chemical Company Disintegrating agent for tablets
US4123382A (en) * 1973-05-25 1978-10-31 Merck & Co., Inc. Method of microencapsulation
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
SE418247B (sv) * 1975-11-17 1981-05-18 Haessle Ab Sett att framstella kroppar med reglerad frigoring av en aktiv komponent
US4016880A (en) * 1976-03-04 1977-04-12 Alza Corporation Osmotically driven active agent dispenser
US4291016A (en) * 1976-07-27 1981-09-22 Sandoz Ltd. Enteric coated mixture of 4-(2-hydroxy-3-isopropylamino-propoxy) indole and sodium lauryl sulphate
GB1542414A (en) * 1976-08-19 1979-03-21 Standard Telephones Cables Ltd Arrangements for the controlled release of biologically active materials
DE2642032C2 (de) * 1976-09-18 1987-04-30 Rupprecht, Herbert, Prof. Dr., 8400 Regensburg Verfahren zur Inkorporierung von Wirkstoffen in siliciumdioxidhaltige Trägermaterialien und eine siliciumdioxidhaltige Zubereitung
GB1576376A (en) * 1977-03-30 1980-10-08 Benzon As Alfred Multiple-unit drug dose
US4256108A (en) * 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
SE426548B (sv) * 1978-12-05 1983-01-31 Haessle Ab Fast farmaceutisk beredning innehallande en terapeutiskt effektiv hjertglykosid och en polymer
US4357469A (en) * 1979-06-14 1982-11-02 Forest Laboratories, Inc. Carrier base material for prolonged release therapeutic compositions
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4309406A (en) * 1979-07-10 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4309404A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
DE3033919A1 (de) * 1980-09-09 1982-04-22 Bayer Ag, 5090 Leverkusen Feste arzneizubereitungen enthaltend nifedipin und verfahren zu ihrer herstellung
CH655658B (xx) * 1980-09-18 1986-05-15
US4439195A (en) * 1980-10-14 1984-03-27 Alza Corporation Theophylline therapy
US4326525A (en) * 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4428883A (en) * 1981-03-06 1984-01-31 The University Of Kentucky Research Foundation Novel method of administering β-blockers and novel dosage forms containing same
IT1144911B (it) * 1981-03-19 1986-10-29 Pharmatec Spa Composizione farmaceutica a rilascio controllato contenente ibuprofen
GB2098867B (en) * 1981-05-21 1984-10-24 Wyeth John & Brother Ltd Sustained release pharmaceutical composition
JPS57209223A (en) * 1981-06-19 1982-12-22 Tanabe Seiyaku Co Ltd Microcapsule for intracranial anti hypotension and its production
US4369272A (en) * 1981-07-07 1983-01-18 E. I. Du Pont De Nemours And Company Process for preparing polyolefin resin extended pigments comprising salt milling crude pigment with the resin
US4484921A (en) * 1982-02-01 1984-11-27 Alza Corporation Theophylline therapy utilizing osmotic delivery
US4434153A (en) * 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
US4449983A (en) * 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4642233A (en) * 1982-03-22 1987-02-10 Alza Corporation Gastrointestinal drug delivery system comprising a hydrogel reservoir containing a plurality of tiny pills
US4649043A (en) * 1982-03-22 1987-03-10 Alza Corporation Drug delivery system for delivering a plurality of tiny pills in the gastrointestinal tract
JPS58170712A (ja) * 1982-03-31 1983-10-07 Chiyoda Yakuhin Kk インドメタシン徐放錠
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
US4681583A (en) * 1982-12-20 1987-07-21 Alza Corporation System for dispersing drug in biological environment
US4578075A (en) * 1982-12-20 1986-03-25 Alza Corporation Delivery system housing a plurality of delivery devices
DE3247118A1 (de) * 1982-12-20 1984-06-20 Cassella Ag, 6000 Frankfurt Neue substituierte 1,4-dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3307422A1 (de) * 1983-03-03 1984-09-06 Bayer Ag, 5090 Leverkusen Fluessigzubereitungen von dihydropyridinen, ein verfahren zu ihrer herstellung, sowie ihre verwendung bei der bekaempfung von erkrankungen
PH18946A (en) * 1983-04-21 1985-11-14 Elan Corp Plc Controlled absorption pharmaceutical composition
GB2146531B (en) * 1983-09-15 1987-04-29 Stc Plc Controlled release system
SE457505B (sv) * 1984-01-10 1989-01-09 Lejus Medical Ab Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
JPH0759499B2 (ja) * 1984-02-10 1995-06-28 ベンツォン ファーマ エイ／エス 拡散被覆された複合単位服用剤
GB2154874B (en) * 1984-02-29 1987-11-04 Sandoz Ltd Bromoscriptine compositions
IT1206166B (it) * 1984-07-26 1989-04-14 Sigma Tau Ind Farmaceuti Dispositivo per rilasciare una sostanza in un fluido di dissoluzione con cinetica di ordine zero e procedimento per la sua preparazione
US4794111A (en) * 1984-05-23 1988-12-27 Bayer Aktiengesellschaft Dihydropyridine preparations containing β-blockers
DE3419131A1 (de) * 1984-05-23 1985-11-28 Bayer Ag, 5090 Leverkusen Dihydropyridinkombinationspraeparate und verfahren zu ihrer herstellung
GB2159715B (en) * 1984-06-04 1988-05-05 Sterwin Ag Pharmaceutical composition in sustained release unit dose form and process for its preparation
SE455836B (sv) * 1985-10-11 1988-08-15 Haessle Ab Beredning med kontrollerad frisettning innehallande ett salt av metoprolol samt metod for framstellning av denna beredning
US4808413A (en) * 1987-04-28 1989-02-28 E. R. Squibb & Sons, Inc. Pharmaceutical compositions in the form of beadlets and method

Also Published As

Publication number Publication date
EP0311582A1 (en) 1989-04-12
CA1312286C (en) 1993-01-05
NZ226245A (en) 1990-08-28
PT88711B (pt) 1992-12-31
ES2053815T3 (es) 1994-08-01
FI92903C (fi) 1995-01-25
ATE84412T1 (de) 1993-01-15
IL87922A0 (en) 1989-03-31
HU210461A9 (en) 1995-04-28
AU2237488A (en) 1989-04-13
JP2619936B2 (ja) 1997-06-11
FI884636A (fi) 1989-04-09
IS1584B (is) 1996-03-01
MX169243B (es) 1993-06-25
DK558688A (da) 1989-04-09
JPH01128917A (ja) 1989-05-22
NO884269D0 (no) 1988-09-27
DE3877492D1 (de) 1993-02-25
IL87922A (en) 1993-07-08
EP0311582B1 (en) 1993-01-13
KR960009411B1 (en) 1996-07-19
KR890006226A (ko) 1989-06-12
NO177375B (no) 1995-05-29
AU615211B2 (en) 1991-09-26
DE3877492T2 (de) 1993-05-13
IE63084B1 (en) 1995-03-22
HK6296A (en) 1996-01-19
IE882921L (en) 1989-04-08
MY104065A (en) 1993-11-30
CN1029935C (zh) 1995-10-11
FI884636A0 (fi) 1988-10-07
DK175085B1 (da) 2004-05-24
NO177375C (no) 1995-09-06
IS3398A7 (is) 1989-04-09
CN1032490A (zh) 1989-04-26
PH25568A (en) 1991-08-08
NO884269L (no) 1989-04-10
US4942040A (en) 1990-07-17
SE8703881D0 (sv) 1987-10-08
GR3006788T3 (xx) 1993-06-30
FI92903B (fi) 1994-10-14
DK558688D0 (da) 1988-10-06

Similar Documents

Publication Publication Date Title
CY1896A (en) Pharmaceutical preparation with extended release of a dihydropyridine and a beta-adrenoreceptor antagonist and a process for the preparation thereof
HUT62784A (en) Process for producing pharmaceutical compositions of elongated release, with ph-controlled membrane
EP0302020A3 (en) Process for the preparation of 2,2,6,6-tetramethyl-4-piperidyl-amines
GR3001619T3 (en) Process for the preparation of (2,2)-paracyclophane
HUT45499A (en) Process for producing optically active 1,4-dihydropyridine derivatives
PT84959A (en) Process for the preparation of novel 1,4-dihydropyridines
EP0300323A3 (en) Process for the preparation of aliphatic n,n-dialkyl substituted aminoalcohols
EP0371492A3 (en) Process for the preparation of 1,4-dihydropyridine derivatives
HUT49124A (en) Process for producing 1-propargyl-2,4-dioxo-imidazolidine
CY1760A (en) Process for the preparation of 1,4-dihydropyridine derivatives
EP0359118A3 (en) Method for the production of 1,1,2-trialkoxyethanes
EP0297239A3 (en) Process for the preparation of hexadiin(2,4)-diol-1,6
PL277260A1 (en) Method of obtaining novel derivatives of tetrahydropyridine
YU78388A (en) Process for obtaining 1,4-dihydropyridine
PH24488A (en) Process for the preparation of aryl-pyrido (1,4)-benzodiazepines
HUT54615A (en) Process for producing n,n-dimethyl-amino-methyl-aryl-derivatives
AR243881A1 (es) Procedimiento de preparacion de derivados de 1,4-dihidropiridina.
EP0381040A3 (en) Method for the preparation of 2,2-dialkylpropionaldehydes
IE882401L (en) Process for preparing n(6)-benzyloxycarbonyl-2,¹6-diaminopimelamic acid
HUT54647A (en) Process for producing nifedipine
YU151489A (en) Process for preparing 2,6-dibromine-izonicotinic acid
YU65689A (en) Process for preparing 7-and-(1-/s/-carboetoxy-3-phenylpropyl-/s/-alanyl/-1,4-dithia-7-azaspyro-/4,4/-nonan-8/s/-carboxylic acid
ZA883610B (en) A process for the preparation of 5-acylamino-2,4,6-triiodo-or tribromo-benzioc acid derivatives and the acid derivatives obtained by said process
YU161988A (en) Process for making small pearls, which contains medicine
RO101150B1 (en) 2,4,4,4-tetrachlorbutyric acid production method